China Resources Pharmaceutical Group Stock Analysis (April 2026)

China Resources Phar...

SEHK:3320

HK$ 6,34

+ HK$0,04 (0,63%)

6,34 HK$

+HK$0,04 (0,63%)

End-of-day quote: 04/10/2026

China Resources Pharmaceutical Group Stock Value

The current analyst rating for SEHK:3320 is Outperform.

Outperform

China Resources Pharmaceutical Group Company Info

EPS Growth 5Y

-7,07%

Market Cap

HK$39,83 B

Long-Term Debt

HK$24,33 B

Quarterly earnings

08/25/2026 (E)

Dividend

HK$0,22

Dividend Yield

3,53%

Founded

2007

Industry

Health Care

Country

Hong Kong

Website

China Resources Pharmaceutical Group

ISIN Number

HK0000311099

Website

http://www.crpharm.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

HK$7,00

10.41%

Last Update: 04/11/2026

Analysts: 9

Highest Price Target HK$7,52

Average Price Target HK$7,00

Lowest Price Target HK$5,90

In the last five quarters, China Resources Pharmaceutical Group’s Price Target has fallen from HK$7,71 to HK$7,38 - a -4,28% decrease. Six analysts predict that China Resources Pharmaceutical Group’s share price will increase in the coming year, reaching HK$7,00. This would represent an increase of 10,41%.

Top growth stocks in the health care sector (5Y.)

What does China Resources Pharmaceutical Group do?

China Resources Pharmaceutical Group Limited engages in the manufacturing, distribution, and retail of pharmaceutical and healthcare products in China. Business Segments The company operates primarily through various business segments which are categorized based on its comprehensive suite of pharmaceutical manufacturing, distribution, and retail operations. Within these segments, the core focus remains on the research, production, and sale of pharmaceuticals, supplemented by a robust distribut...

China Resources Pharmaceutical Group Limited engages in the manufacturing, distribution, and retail of pharmaceutical and healthcare products in China.

Business Segments

The company operates primarily through various business segments which are categorized based on its comprehensive suite of pharmaceutical manufacturing, distribution, and retail operations. Within these segments, the core focus remains on the research, production, and sale of pharmaceuticals, supplemented by a robust distribution and retail network.

Manufacturing

The manufacturing segment takes pride in producing a wide array of pharmaceutical products spanning across chemical drugs, biological drugs, and traditional Chinese medicines. Each product line is developed to target specific health conditions and therapeutic areas, fulfilling the diverse healthcare needs of the population. The emphasis on quality control and regulatory compliance guarantees that the manufactured products meet the stringent standards set forth by the pharmaceutical industry.

Distribution Segment

The distribution arm plays a pivotal role in the company's operations. Various strategies are implemented to maintain efficient distribution systems that ensure timely delivery of products to medical institutions, hospitals, and retail pharmacies. The development of logistics centers allows for the optimization of supply chain operations, enabling quick response times to market demands.

Retail Segment

The retail segment of the company focuses on enhancing customer accessibility to pharmaceutical products. With a network of retail pharmacies positioned strategically nationwide, the aim is to reach consumers directly, providing them with essential medicines, health products, and personal care items. This segment is also pivotal in fostering relationships with end-users, providing them with consultation services alongside pharmaceutical products.

Business Strategy

The company embraces a multifaceted business strategy that emphasizes innovation and market expansion as key pillars. The commitment to research and development is underscored by the significant resources allocated to enhance product offerings and improve existing formulas.

Moreover, the company strategically targets expansion within the growing Chinese healthcare market, which encompasses chronic illness management, preventive healthcare products, and overall health management solutions. By diversifying product lines and increasing market penetration, the company strives to meet the evolving needs of consumers.

Additionally, the integration of a robust digital strategy enhances the marketing and distribution processes, allowing for greater engagement with healthcare professionals and consumers alike. This transformation includes the utilization of digital platforms for marketing, customer relationship management, and data analytics, which ultimately aids in driving growth and fostering competitive advantages.

Products and Services

Pharmaceutical Products

The company offers a diverse range of pharmaceutical products spanning multiple categories, designed to address various health conditions. The product portfolio includes chemical drugs, biological products, traditional Chinese medicine, and healthcare items.

Therapeutic Areas

The company's offerings include cardiovascular health, metabolic diseases, pediatric treatments, gastrointestinal issues, dermatological conditions, and respiratory ailments, among others.

Over-The-Counter Medicines

The company also provides over-the-counter medicines catering to common ailments. Moreover, nutritional supplements and wellness products are included in the portfolio, responding to growing consumer awareness regarding health and personal care.

Services

The company emphasizes access to medical guidance and patient education through its retail pharmacies. These facilities provide consultations, ensuring that customers are well-informed about their medication and health management options.

Geographical Markets Served

The company primarily operates within the Chinese pharmaceutical market, leveraging the vast population and increasing healthcare demands.

Seasonality

The company likely experiences some seasonal fluctuations in demand patterns, particularly within certain therapeutic areas and retail pharmacies. For instance, an upsurge in cold and flu medications is often observed during the winter months, whereas there may be an increase in sales for allergy and respiratory medications during the spring season.

Customers

The company serves a diverse clientele, primarily consisting of medical institutions, hospitals, and retail consumers. Major customers include over 10,667 second- and third-class hospitals, alongside nearly 100,000 primary medical institutions throughout China.

Sales and Marketing

The company employs a multifaceted sales and marketing approach to reach its consumers and medical institutions. This includes direct sales to hospitals, partnerships with healthcare professionals, and marketing initiatives targeting end-users directly through retail pharmacies.

Distribution channels are fortified by an extensive logistics network, ensuring that products are delivered efficiently to various clients nationwide. Sales representatives engage with medical institutions to provide product information and facilitate orders, fostering strong relationships within the healthcare sector.

With the rise of digital platforms, the company enhances its marketing strategy through various digital channels, including social media and online retail options, aiming to engage younger consumers and improve overall accessibility to its products.

History

The company was founded in 2007. It was incorporated in 2007. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in 2011.

China Resources Pharmaceutical Group Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical Products:** approximately 65% of total revenue **Health Products:** approximately 20% of total revenue **Medical Devices:** approximately 15% of total revenue **TOP 3 Markets:** 1. **China:** approximately 70% 2. **Southeast Asia:** approximately 15% 3. **Europe:** appr...

At which locations are the company’s products manufactured?

**Production Sites:** Mainly in China China Resources Pharmaceutical Group Limited produces the majority of its products in China. The company has several production facilities throughout the country specializing in the manufacturing of pharmaceutical products, traditional Chinese medicines, and ot...

What strategy does China Resources Pharmaceutical Group pursue for future growth?

**Focus on Research and Development:** Increase in R&D spending by 20% (2024) **Market Expansion:** Planned expansion into new markets in Southeast Asia (2025) **Digitalization:** Investment in digital health platforms China Resources Pharmaceutical Group Limited is pursuing a multi-pronged g...

Which raw materials are imported and from which countries?

**Main Imported Raw Materials:** Active Pharmaceutical Ingredients (APIs), Excipients, Packaging Materials **Main Import Countries:** India, Germany, USA China Resources Pharmaceutical Group Limited imports a variety of raw materials necessary for the production of their pharmaceutical products. T...

How strong is the company’s competitive advantage?

**Market share in China:** Approximately 5% (estimated, 2025) **R&D expenses:** 4% of revenue (2025) **Industry growth in China:** 8% (2025) China Resources Pharmaceutical Group Limited (CR Pharma) has a significant competitive advantage due to its strong market presence and the support of...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 55% (estimated for 2025 based on historical trends) **Insider Trades:** No significant transactions in the last 12 months (as of 2025) The institutional investor share in China Resources Pharmaceutical Group Limited is approximately 55%. This indicates a strong in...

What percentage market share does China Resources Pharmaceutical Group have?

**Market share of China Resources Pharmaceutical Group Limited:** 6.5% (2025, estimated) **Top competitors and their market shares:** 1. **Sinopharm Group Co. Ltd.:** 12.0% 2. **Shanghai Pharmaceuticals Holding Co. Ltd.:** 8.5% 3. **China Resources Pharmaceutical Group Limited:** 6.5% 4. **CSPC Pha...

Is China Resources Pharmaceutical Group stock currently a good investment?

**Revenue Growth:** 8.5% (2024) **Profit Growth:** 6.2% (2024) **R&D Expenses:** 5.1% of revenue (2024) China Resources Pharmaceutical Group Limited recorded solid revenue growth of 8.5% in 2024, attributed to strong demand for pharmaceutical products and an effective distribution strategy. The...

Does China Resources Pharmaceutical Group pay a dividend – and how reliable is the payout?

**Dividend Yield:** 3.5% (estimated for 2025) **Dividend History:** Consistent payout over the last 5 years China Resources Pharmaceutical Group Limited has regularly distributed dividends in recent years, indicating a certain level of reliability. The dividend yield is estimated to be around 3.5...

New support ticket

Explore

China Resources Pharmaceutical Group Stock Value

China Resources Pharmaceutical Group Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does China Resources Pharmaceutical Group do?

China Resources Pharmaceutical Group Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

China Resources Pharmaceutical Group Stock Value

China Resources Pharmaceutical Group Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does China Resources Pharmaceutical Group do?

China Resources Pharmaceutical Group Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.